Search
GI Cancer
EAQ162CD
Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent
EA2165
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
SWOG 1613
A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
URCC 16092 Pending RN training
Phase II Study of Exercise and Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy
A021502 (NCT02912559)
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
EA2161 (NCT02893930) (temporarily suspended 11/5/18)
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
NRG RTOG1112 (NCT01730936) – PENDING RT CREDENTIALING
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
NRG GI002 (NCT02921256) – ONLY AVAILABLE CURRENTLY AT MBMC – MUST BE RT CREDENTIALED.
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
NCTG N1048 (PROSPECT) (NCT01515787) – ONLY AVAILABLE AT MBMC – MUST BE RT CREDENTIALED
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
S1417CD (NCT02728804)
Implementation of a Prospective Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer
